Core Viewpoint - Haizheng Biomedical Materials (688203.SH) forecasts a significant decline in net profit for the year 2025, projecting a profit of 7.5 million to 9.5 million yuan, which represents a decrease of 26.0046 million to 28.0046 million yuan compared to the previous year, equating to a year-on-year decline of 73.24% to 78.88% [1] Group 1 - The company reports steady progress in production and operations, with an upward trend in the sales volume of its main products [1] - The company is actively expanding and deepening its domestic market presence, resulting in increased sales revenue [1] - Market competition has led to downward pressure on product sales prices, which has compressed the gross profit margin [1] Group 2 - There has been a year-on-year decrease in interest income and foreign exchange gains, contributing to an increase in financial expenses [1] - The transition of construction projects from fundraising investments to fixed assets has resulted in higher depreciation and tax expenses, further squeezing profits for the period [1]

Core Viewpoint - The company, Luban Chemical (600727.SH), expects a significant decrease in profits for the year 2025, projecting a total profit of approximately 150 million yuan and a net profit attributable to shareholders of around 42.11 million yuan, primarily due to declining market demand and increased competition in the titanium dioxide and basic chemical product sectors [1]. Group 1: Financial Projections - The company anticipates a total profit of about 150 million yuan for 2025 [1] - The expected net profit attributable to shareholders is approximately 42.11 million yuan [1] - The projected net profit after deducting non-recurring gains and losses is around 40.34 million yuan [1] Group 2: Reasons for Profit Decrease - The profitability of titanium dioxide products has significantly narrowed due to weak market demand, influenced by a deep adjustment in the domestic real estate sector and a slowdown in infrastructure investment [1] - The demand for end-use coatings and pigments remains persistently low, leading to intensified competition in the titanium dioxide market, characterized by a simultaneous decline in both volume and price [1] - Despite efforts to optimize processes and reduce unit costs, the negative impact of falling product prices has not been offset, resulting in a reduced gross margin and lower profit per ton [1] - Basic chemical products are experiencing cyclical price declines due to supply-demand mismatches, with the chemical commodity market undergoing a destocking phase [1] - Specifically, the sales volume and prices of methylene chloride products have decreased due to fluctuations in demand from downstream refrigerant and solvent industries, significantly reducing their gross profit contribution compared to the previous year [1] - Additionally, the sales price of raw salt products has dropped significantly year-on-year due to intensified market competition, leading to a marked decline in profitability for this business segment [1]

Core Viewpoint - Zhongyuan New Materials (603527.SH) has announced a profit warning for the fiscal year 2025, projecting a net profit attributable to shareholders of the parent company between 52 million to 71 million yuan, representing a decrease of 56.29 million to 75.29 million yuan compared to the previous year, which translates to a year-on-year decline of 44.22% to 59.15% [1] Group 1 - The primary reason for the profit warning is that the company's subsidiaries and new projects have not yet achieved large-scale production, leading to an inability to fully realize benefits, while depreciation and fixed costs have significantly increased after capitalizing on investments, impacting profits [1] - The company is facing intensified market competition, resulting in a downward trend in product processing fees, which has also negatively affected profitability [1] - To ensure long-term development, the company has increased its R&D investment this year, leading to a short-term rise in related expenses that has impacted profits [1]

Core Viewpoint - The company, Luban Chemical (600727.SH), expects a significant decrease in profits for the year 2025, projecting a total profit of approximately 150 million yuan and a net profit attributable to shareholders of around 42.11 million yuan, primarily due to declining market demand and increased competition in the titanium dioxide and basic chemical product sectors [1]. Group 1: Financial Projections - The company anticipates a total profit of about 150 million yuan for 2025 [1] - The expected net profit attributable to shareholders is around 42.11 million yuan [1] - The projected net profit after deducting non-recurring gains and losses is approximately 40.34 million yuan [1] Group 2: Reasons for Profit Decrease - The profitability of titanium dioxide products has significantly narrowed due to weak market demand, influenced by a deep adjustment in the domestic real estate sector and a slowdown in infrastructure investment [1] - The end-market demand for coatings and pigments remains sluggish, leading to intensified competition in the titanium dioxide market, characterized by a simultaneous decline in both volume and price [1] - Despite cost reductions through process optimization, the negative impact of falling product prices has not been offset, resulting in a reduced gross margin and lower profit per ton [1] - Basic chemical products are experiencing cyclical price declines due to supply-demand mismatches, with the chemical commodity market undergoing a destocking phase [1] - Specifically, the sales volume and prices of methylene chloride products have decreased due to fluctuations in demand from downstream refrigerant and solvent industries, significantly reducing their gross profit contribution compared to the previous year [1] - Additionally, the sales price of raw salt products has dropped significantly year-on-year due to intensified market competition, leading to a marked decline in profitability for this business segment [1]

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a decrease of 88.70% to 92.47% compared to the previous year, with net profit attributed to shareholders estimated between 4 million to 6 million yuan [1] Group 1: Financial Performance - The projected net profit for 2025 is between 4 million to 6 million yuan, indicating a substantial year-on-year decrease [1] - The net profit excluding non-recurring losses is expected to be between -12 million to -7 million yuan [1] Group 2: Factors Affecting Performance - The decline in performance is primarily due to the impact of the U.S. FDA import warnings and increased tariffs, which have altered the company's product sales structure and reduced overall gross profit margins [1] - The company is accelerating the construction and production of its facility in Cambodia to adapt to external environmental changes, which has led to increased fixed costs and initial production inefficiencies [1] - Additional costs have been incurred for the registration and certification of new products as part of the company's business layout strategy [1] - The company has recognized impairment losses on certain assets based on prudence principles in accordance with accounting standards [1]

Core Viewpoint - Honghe Technology is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 72.74% to 77.24% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 50.5 million to 60.5 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 20 million and 30 million yuan, reflecting a year-on-year decrease of 82.91% to 88.61% [1] Market Conditions - The decline in revenue is attributed to fluctuations in overseas market demand and intensified competition within the domestic industry [1] - Recent quality issues with certain raw materials have led the company to increase expense provisions based on prudence, further negatively impacting current performance [1]

南财智讯1月30日电，博瑞医药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 4130万元—6190万元，同比预减67.28%—78.17%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为430万元—2490万元，同比预减86.21%—97.62%。2025年公司归属于母公司所有者的 净利润预计同比减少67.28%到78.17%，归属于母公司所有者的扣除非经常性损益的净利润预计同比减 少86.21%到97.62%，主要受流感趋势变化、竞争格局变化、客户阶段性商业需求波动等影响，使得当 期营业收入及产品毛利额减少，以及在建工程陆续完工转固带来计提折旧增加，同时创新药等研发投入 加大使得研发费用等期间费用同比有所增加。 ...

格隆汇1月30日｜鲁北化工公告，预计2025年度实现归属于母公司所有者的净利润4211万元左右，与上 年同期的2.61亿元相比，将减少2.19亿元左右，同比减少83.87%左右。预计2025年度实现归属于母公司 所有者的扣除非经常性损益的净利润4034万元左右，与上年同期的2.68亿元相比，将减少2.28亿元左 右，同比减少84.97%左右。公司2025年度业绩预减的主要原因在于钛白粉产品盈利能力因市场需求疲 软大幅收窄，以及基础化工产品受供需错配影响，价格呈周期性回落。 ...

Core Viewpoint - The company, Tenglong Co., Ltd., anticipates a significant decline in net profit for the year 2025, projecting a decrease of 72.38% to 81.59% compared to the previous year, primarily due to various operational and accounting factors [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 46 million and 69 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 28.8 million and 51.8 million yuan, reflecting a decrease of 72.21% to 84.55% year-on-year [1] - The anticipated operating revenue for 2025 is estimated to be between 396.46 million and 438.2 million yuan, indicating a year-on-year increase of 3.97% to 14.92% [1] Group 2: Reasons for Profit Decline - The main reasons for the profit decline include intensified industry competition and the depreciation of fixed assets from new projects in Poland and Anhui, which are currently in the capacity ramp-up phase [1] - The absence of non-operating gains from the previous year, specifically the asset disposal gain of 66.3 million yuan from the Tenglong Road No. 1 plant, significantly impacts the year-on-year profit comparison [1] - The company plans to recognize goodwill and long-term equity investment impairment losses totaling approximately 146 million to 161 million yuan due to the underperformance of subsidiaries and associated companies, which will have a substantial effect on overall performance [1]

腾龙股份公告称，预计2025年度营业收入39.65亿至43.82亿元，同比增加3.97%至14.92%；归属于母公 司所有者的净利润4600.00万元至6900.00万元，同比减少约81.59%至72.38%。业绩预减主因行业竞争加 剧、新投项目产能爬坡期折旧分摊大致毛利率下滑；上年有资产处置收益而本期无；预计计提商誉及长 期股权投资减值1.46亿至1.61亿元。 ...